{
  "id": 11131404,
  "title": "Sidra Medicine introduces two new specialised therapies for children with high-risk neuroblastoma",
  "url": "https://urgent.news/2026/10/01/sidra-medicine-introduces-two-new-specialised-therapies-for-children",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T07:02:12.000Z",
  "source": {
    "name": "The Peninsula Qatar",
    "slug": "the-peninsula-qatar",
    "url": "https://thepeninsulaqatar.com/article/01/10/2026/sidra-medicine-introduces-two-new-specialised-therapies-for-children-with-high-risk-neuroblastoma"
  },
  "original_language": "en",
  "account": "Doha, Qatar - In September, to conclude Childhood Cancer Awareness Month, Sidra Medicine celebrated two major achievements in pediatric cancer care: the introduction of two specialized therapies for children with high-risk neuroblastoma. These therapies, naxitamab (Danyelza) and dinutuximab beta (Qarziba), are anti-GD2 monoclonal antibody treatments used to combat neuroblastoma, a cancer affecting nerve tissue in babies and young children, often before they reach five years old.\n\nDr. Chiara Cugno, the Acting Division Chief of Paediatric Haematology and Oncology at Sidra Medicine, stated that the implementation of these complex therapies entailed significant preparation and collaboration among various medical, surgical, nursing, pharmacy, educational, and multidisciplinary teams. This development underscores Sidra Medicine's dedication to enhancing pediatric cancer treatment and care, while also broadening access to specialized therapies for children and their families in Qatar.\n\nThe first patient to receive naxitamab in Qatar and the GCC was Issa, who was diagnosed with neuroblastoma at birth. Issa was treated at Sidra Medicine with a combination of chemotherapy and autologous transplantation, followed by the administration of the anti-GD2 monoclonal antibody. Issa's father expressed his gratitude, stating that the exceptional team at Sidra Medicine, renowned for its high international standards of care, played a crucial role in supporting and celebrating each milestone of his son's journey.",
  "summary": "<p>Doha, Qatar: To close Childhood Cancer Awareness Month this September, Sidra Medicine has marked two significant milestones in paediatric cancer care, following the introduction of two specialized therapies for children with high-risk neuroblastoma.</p> <p>Sidra Medicine’s Paediatric Haematology and Oncology and Haematopoietic Stem Cell Transplant ( HSCT) teams have successfully administered…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Gulf Times",
        "title": "Sidra introduces 2 specialised therapies for children with high-risk neuroblastoma",
        "url": "https://urgent.news/2026/09/30/sidra-introduces-2-specialised-therapies-for-children-with-high-risk",
        "published": "2026-09-30T21:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}